PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease.
about
Vinpocetine as a potent antiinflammatory agentThe selective phosphodiesterase 4 inhibitor roflumilast and phosphodiesterase 3/4 inhibitor pumafentrine reduce clinical score and TNF expression in experimental colitis in miceMatrix-specific protein kinase A signaling regulates p21-activated kinase activation by flow in endothelial cellsPhosphodiesterase 4D and 5-lipoxygenase activating protein in ischemic stroke.Cyclic AMP dysregulates intestinal epithelial cell restitution through PKA and RhoADoxofylline: a promising methylxanthine derivative for the treatment of asthma and chronic obstructive pulmonary disease.Tuning inflammation with anti-inflammatory neuropeptides.Tuning immune tolerance with vasoactive intestinal peptide: a new therapeutic approach for immune disordersEnantiomer discrimination illustrated by the high resolution crystal structures of type 4 phosphodiesterasePhosphodiesterase 4 inhibitors and inflammatory bowel disease: emerging therapies in inflammatory bowel disease.Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy.Treating COPD with PDE 4 inhibitors.Endogenous anti-inflammatory neuropeptides and pro-resolving lipid mediators: a new therapeutic approach for immune disorders.Phosphodiesterase 4D single-nucleotide polymorphism 83 and cognitive dysfunction in carotid endarterectomy patients.Tetomilast: new promise for phosphodiesterase-4 inhibitors?Apremilast for the treatment of psoriasis.Roflumilast inhibits leukocyte-endothelial cell interactions, expression of adhesion molecules and microvascular permeability.Immunotherapeutic effects of pentoxifylline in type 1 diabetic mice and its role in the response of T-helper lymphocytes.A new structure-based QSAR method affords both descriptive and predictive models for phosphodiesterase-4 inhibitors.Beneficial effect of phosphodiesterase-5 inhibitor in experimental inflammatory bowel disease; molecular evidence for involvement of oxidative stress.Tetomilast suppressed production of proinflammatory cytokines from human monocytes and ameliorated chronic colitis in IL-10-deficient mice.Lipopolysaccharide administration in vivo induces differential expression of cAMP-specific phosphodiesterase 4B mRNA splice variants in the mouse brain.Osthole pretreatment alleviates TNBS-induced colitis in mice via both cAMP/PKA-dependent and independent pathways.Sex-related differences of cAMP-specific PDE4B3 mRNA in oligodendrocytes following systemic inflammation.Molecular Docking Study Based on Pharmacophore Modeling for Novel PhosphodiesteraseIV Inhibitors.
P2860
Q28283160-D5A413D9-181C-4B46-9B6A-A30871DB0D9BQ28487329-BE106ECC-F599-4EDB-9E3D-55C029E39CF5Q30432582-1E6AA9C7-CB16-4FA3-87C1-A470E3E3BBF0Q30445412-2C3AE840-894A-4F25-9103-36FCECC06238Q31034056-18974F9C-8386-4A0D-A614-A050A3F06F78Q34997202-D8BA65B4-16EF-4996-BDD0-9FA6E0513E7FQ36764912-2EB9C7DB-4FA2-4513-8DA8-86E8F55A8933Q36830470-8398A205-B9E2-453C-9522-30E536739A2BQ36855547-17B243BF-03DF-499E-A5B0-FEC7DD0C4E6AQ36916892-BA009EC6-4A19-4F42-8C12-0E6BA113A4B6Q36969911-83247CC8-F08F-4E2C-A09B-2AAA2774DC24Q37082594-6BB72A1A-9346-47AC-A613-1FD713F45A49Q37191369-0D1EE7D0-2508-4442-86AC-C92244D1D6FCQ37604267-E3F5A0D4-B411-40F7-9280-6648FCD2DDBBQ38050167-2902A408-A856-46DB-B486-A07D1D94A2BCQ38561061-F21AA282-3751-4D13-9E30-D7EF1A50FB55Q39322017-CE4C7A66-20EB-4FEA-BF56-7E532AB17677Q40101442-CF06E344-34DB-4AF3-A23A-5D93DC4FCA9DQ42941297-3752A96B-71C1-482E-B8A9-C4757E3A8990Q43215812-F2BA6E72-110C-46D4-BAEF-8BE996ED86FDQ43766971-5E1C72D7-FD75-47DA-B6CF-266BE1F494F1Q49059546-A8F1F989-0A73-4133-866C-1ED4DE62137CQ50590433-267408C0-A5A3-436E-8855-DB8359FF3E09Q51321537-9C090A4E-3415-401A-8270-E626DE4E652CQ51603501-BE6EBA85-32BD-4AD7-B20A-30E22F861B77
P2860
PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease.
@ast
PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease.
@en
type
label
PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease.
@ast
PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease.
@en
prefLabel
PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease.
@ast
PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease.
@en
P1476
PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease.
@en
P2093
Katharine H Banner
Michael A Trevethick
P304
P356
10.1016/J.TIPS.2004.06.008
P577
2004-08-01T00:00:00Z